Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Archives of Gynecology and Obstetrics

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00404-011-2166-5PMID 22159627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis

  2011cited by this paper
• Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma

  2010cited by this paper
• Survival of cancer cells is maintained by EGFR independent of its kinase activity.

  2008cited by this paper
• Expression of SGLT1, Bcl-2 and p53 in Primary Pancreatic Cancer Related to Survival

  2008cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer

  2006cited by this paper
• Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck

  2004cited by this paper
• Why do cancers have high aerobic glycolysis?

  2004cited by this paper
• Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck.

  2004cited by this paper
• Treatment of ovarian cancer: new strategies.

  2003cited by this paper
• Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.

  2003cited by this paper
• Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins

  2003cited by this paper
• High levels of intracellular ATP prevent nitric oxide‐induced apoptosis in rat gastric mucosal cells

  2003cited by this paper
• SGLT Gene Expression in Primary Lung Cancers and Their Metastatic Lesions

  2001cited by this paper
• Glucose Uptake and Glycolysis Reduce Hypoxia-induced Apoptosis in Cultured Neonatal Rat Cardiac Myocytes*

  1999cited by this paper
• Cancer incidence and mortality, 1973-1995: a report card for the U.S.

  1998cited by this paper
• Cancer incidence and mortality, 1973‐1995

  1998cited by this paper
• Mitochondrial dysfunction and cytoskeletal disruption during chemical hypoxia to cultured rat hepatic sinusoidal endothelial cells: The pH paradox and cytoprotection by glucose, acidotic pH, and glycine

  1998cited by this paper
• Genetics and ovarian carcinoma.

  1998cited by this paper
• 'Active' sugar transport in eukaryotes.

  1994cited by this paper
• Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in Caco-2 cell clones in relation to cell growth and glucose consumption.

  1994cited by this paper
• Extracellular ATP and adenosine modulate tumor necrosis factor-induced lysis of L929 cells in the presence of actinomycin D.

  1991cited by this paper
• Receiver operating characteristic (ROC) methodology: the state of the art.

  1989cited by this paper
• Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

  1987cited by this paper

• Investigation of Cytotoxic Effects of Empagliflozin on Caco-2, LNCaP and A2780 Human Cancer Cell Lines

  2026cites this paper
• Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study.

  2025cites this paper
• Landscape of metabolic alterations and treatment strategies in breast cancer

  2025cites this paper
• Molecular mechanisms of glucose metabolism disorders in tumors of the female reproductive system

  2025cites this paper
• PET imaging of sodium-glucose cotransporters (SGLTs): Unveiling metabolic dynamics in diabetes and oncology

  2024cites this paper
• Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.

  2024cites this paper
• Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review

  2024cites this paper
• Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models

  2024cites this paper
• Antidiabetic agents as potential cytotoxic candidates for cancer therapy

  2024cites this paper
• Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy

  2024cites this paper
• Mapping the expression and functional landscape of key enzymes in glucose metabolism within human gynecological tumors.

  2024cites this paper
• SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast

  2023cites this paper
• Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

  2023cites this paper
• Mebendazole targets essential proteins in glucose metabolism leading gastric cancer cells to death.

  2023cites this paper
• The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies

  2023cites this paper
• A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

  2022cites this paper
• Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets

  2022cites this paper
• The “Sweet Spot” of Targeting Tumor Metabolism in Ovarian Cancers

  2022influential citation
• Glucose transporters as markers of diagnosis and prognosis in cancer diseases

  2022cites this paper
• Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases

  2021cites this paper
• CRISPR/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells.

  2021cites this paper
• Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer

  2020cites this paper
• Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer

  2020cites this paper
• Heterogeneity of Glucose Transport in Lung Cancer

  2020cites this paper
• Metabolism and immunity in breast cancer

  2020cites this paper
• CMAR_A_195424 3171..3185

  2019cites this paper
• / aiht-2018-69-3204 Sodium-glucose cotransporters : new targets of cancer therapy ?

  2019cites this paper
• SGLT1 is required for the survival of triple negative breast cancer cells via potentiating EGFR activity

  2019influential citation
• Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor colorectal tumorigenesis in diabetic and obese mice

  2019cites this paper
• SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity

  2019influential citation
• SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK/mTOR signaling

  2019cites this paper
• Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications

  2019cites this paper
• SGLT1 inhibition: Pros and cons

  2018cites this paper
• 2478 / aiht-2018-69-3204 Sodium-glucose cotransporters : new targets of cancer therapy ?

  2018cites this paper
• Black bean peptides inhibit glucose uptake in Caco-2 adenocarcinoma cells by blocking the expression and translocation pathway of glucose transporters

  2018cites this paper
• Sodium-glucose cotransporters: new targets of cancer therapy?

  2018cites this paper
• The Na+‐D‐glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer

  2017cites this paper
• Strategie odżywcze komórek nowotworowych – przegląd wybranych typów nowotworów z uwzględnieniem zmian w poziomie i wzorze ekspresji transporterów glukozy

  2017cites this paper
• EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma.

  2016cites this paper
• The effects of hyperglycemia on glucose metabolism in epithelial ovarian cancer

  2016cites this paper
• Analysis of EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma

  2015cites this paper
• Glycolytic genes in cancer cells are more than glucose metabolic regulators

  2014cites this paper
• Determination of Functional Activity of Sodium Glucose Transporters in Cancer

  2014cites this paper
• A Review on the Relationship between SGLT2 Inhibitors and Cancer

  2014cites this paper
• Targeting the Kinase-Independent Pro-survival Function of EGFR in Prostate Cancer

  2013cites this paper
• EGFR–SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors

  2013cites this paper
• The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors

  2013cites this paper
• Sodium/Glucose Co-transporter 1 Expression Increases in Human Diseased Prostate

  2012cites this paper
• Prediction of response to promising rst-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: Practical biomarkers and robust multiplex models

  year unknowncites this paper
• Practical biomarkers and robust multiplex models for the prediction of response to the promising rst-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumors

  year unknowncites this paper